Gemcitabine 1000 mg clinical trials

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

This study is testing a new drug, pemigatinib, against standard chemotherapy for a type of bile duct cancer (cholangiocarcinoma) that has spread or can't be removed, and has a specific gene change. It wants to see which treatment works better and is safer as a first treatment.